- Health2Sync’s SugarGenie app is experiencing rapid growth and positive reception in South Korea.
- The platform is being utilized in both hospital settings and through government programs. Health2Sync has partnered with Sanofi for hospital rollouts and integrated its solution with South Korea’s Primary Health Care Chronic Disease Management Program, reaching over 100 healthcare institutions by December 2024 for diabetes, hypertension, and obesity care.
- Healthcare professionals praise the app for improving patient care: SugarGenie enhances the ability to monitor patient data, provide personalized guidance, and effectively manage chronic conditions like diabetes.
TAIPEI, TAIWAN – Media OutReach Newswire – 18 February 2025 – Health2Sync, a leading provider of digital therapeutics solutions for chronic diseases, announced today that it is experiencing significant growth and positive feedback from healthcare professionals in South Korea. Since launching its app, SugarGenie, in January 2024, the company has witnessed a surge in adoption among healthcare institutions. The company’s solution offers data integration, visualization, and personal insights to improve patient care quality and streamline clinical workflows.
https://www.linkedin.com/company/health2sync/
https://www.facebook.com/Health2Sync
https://www.instagram.com/goodfoodlab_h2s/
The issuer is solely responsible for the content of this announcement.
About Health2Sync
Founded in 2013, Health2Sync offers digital solutions to help people with chronic diseases, pre-diabetes, or weight concerns to manage their health. The company’s achievements include being the first approved digital therapeutics in Taiwan for their insulin dosage titration software, Insultrate, which they co-developed with Sanofi. The company has also received the “NEXT BIG” Startup title from the Taiwan National Development Council.
For more information, please visit https://www.health2sync.com/
